ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

ADVFN

Trade Now

EasyMarkets
Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P 500
4,567.80
(
0.38%
)
US Tech 100
15,532.00
(
-0.39%
)
Dow Jones
35,950.89
(
1.47%
)
Brent Oil
80.715
(
0.43%
)
Bitcoin
38,100.24
(
1.02%
)
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Chemomab Therapeutics Ltd (CMMB)

  7. Chemomab Therapeutics Ltd (CMMB) News

CMMB Chemomab Therapeutics Ltd

0.539
-0.0207 (-3.7%)
Nov 30 2023 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Chemomab Therapeutics Ltd CMMB NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
Upgrade Icon
-0.0207 -3.7% 0.539 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.5474 0.5282 0.579 0.539 0.5597
more quote information »

Recent News

Date Time Source Heading
11/16/202307:00PRNUSChemomab Presentation at ACR Convergence 2023 Provides..
11/15/202316:35EDGAR2Form SC 13D/A - General statement of acquisition of..
11/15/202307:00PRNUSChemomab Therapeutics Receives FDA Fast Track Designation..
11/13/202308:00PRNUSChemomab Presents New Clinical Data Supporting CM-101's..
11/09/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/09/202308:00PRNUSChemomab Therapeutics Announces Third Quarter 2023 Financial..
11/06/202316:15PRNUSChemomab Therapeutics Discloses Receipt of Nasdaq Notice..
11/06/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
10/30/202308:33EDGAR2Form F-3/A - Registration statement by foreign private..
10/30/202307:00PRNUSChemomab Therapeutics to Report Third Quarter 2023 Financial..
10/26/202307:00PRNUSChemomab Therapeutics to Present at Upcoming Scientific..
10/16/202316:25EDGAR2Form F-3 - Registration statement by foreign private issuers
9/28/202307:00PRNUSChemomab Therapeutics to Present Its CM-101 Clinical Program..
8/29/202307:00PRNUSChemomab Therapeutics to Present at the H.C. Wainwright 25th..
8/14/202308:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/14/202308:00PRNUSChemomab Therapeutics Announces Second Quarter 2023..
8/08/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/05/202317:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/03/202315:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
6/28/202307:00PRNUSChemomab Therapeutics Announces Publication in JCI Insight..
6/26/202307:00PRNUSChemomab Therapeutics Presents Data Reinforcing the Clinical..
6/21/202307:00PRNUSChemomab Therapeutics Reports Positive Data from Secondary..
6/05/202307:00PRNUSChemomab Therapeutics Announces Executive Leadership Changes..
6/02/202309:00PRNUSPatient Data Presented at 2023 EULAR Congress Highlights How..
5/24/202307:00PRNUSChemomab Therapeutics to Participate in Upcoming Scientific..
5/11/202306:00PRNUSChemomab Therapeutics Announces First Quarter 2023 Financial..
4/26/202307:00PRNUSChemomab Therapeutics to Present at 2023 Aegis Virtual..
4/19/202307:00PRNUSChemomab Therapeutics to Present at Upcoming Scientific..
4/12/202307:00PRNUSChemomab Therapeutics to Discuss First Quarter 2023..
3/29/202308:30PRNUSChemomab Therapeutics to Provide a Corporate Update on April..
3/17/202307:00PRNUSChemomab Therapeutics to Discuss Fourth Quarter and..
3/06/202307:00PRNUSChemomab to Present at the Oppenheimer 33rd Annual..
2/21/202307:00PRNUSChemomab Announces FDA Clearance of Investigational New Drug..
1/03/202307:00PRNUSChemomab Reports Top-Line Results from CM-101 Phase 2a Liver..
12/21/202207:00PRNUSChemomab Reports Independent Drug Monitoring Committee..

Your Recent History

NASDAQ
CMMB
Chemomab Therapeutics
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com